These results contradict the previous work by Yong et al. (2014) [14]; however, our work shows directly that HER2 is not expressed in these two DCIS cell lines and agrees with previous work showing that treatment with Herceptin (monoclonal antibody directed against HER2) was not cytotoxic to ETCC cell lines [14]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.